Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals
Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), a...
Gespeichert in:
Veröffentlicht in: | Cancer science 2018-08, Vol.109 (8), p.2383-2390 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2390 |
---|---|
container_issue | 8 |
container_start_page | 2383 |
container_title | Cancer science |
container_volume | 109 |
creator | Masaki, Ayako Ishida, Takashi Suzuki, Susumu Ito, Asahi Narita, Tomoko Kinoshita, Shiori Ri, Masaki Kusumoto, Shigeru Komatsu, Hirokazu Inagaki, Hiroshi Ueda, Ryuzo Iida, Shinsuke |
description | Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease.
The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients. |
doi_str_mv | 10.1111/cas.13654 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6113433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2468550104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</originalsourceid><addsrcrecordid>eNp9kctu1DAUhiMEoqWw4AVQJDbtIp3j-3iDVI2AQRqJBQNby3FOGJckDnEydHaIJ-AZeRI8nbZcJLBknSP70ycf_1n2lMA5SWvmbDwnTAp-LzsmjOtCAcj7170qNDB6lD2K8RKASa75w-yI6jkXCuhx9m05tbbL1z--fnfYNHmza_tNGIfQezdrcPqErbf51g9TzMddjznJT5fr1YfEk7N8ba9SE3t0vvbulwWvNnaKow9d7rv8lk_bdzW6Eat0XPmtrybbxMfZgzoVfHJTT7L3r16uF8ti9fb1m8XFqnBcC14gnxNbga11hYBWa6pZSUARV8pSYa0sEboEyTRIUTEirXJi7mpXEaIsMHaSvTh4-6lssXLYjYNtTD_41g47E6w3f950fmM-hq2RJH0k2wtObwRD-DxhHE3r435e22GYoqHAFRVEcEjo87_QyzANXRrPUC7nQgAB_l-KaqBUEi0TdXag3BBiHLC-ezIBs8_fpPzNdf6Jffb7jHfkbeAJmB2AL77B3b9NZnHx7qD8CY70vzk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290226196</pqid></control><display><type>article</type><title>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Masaki, Ayako ; Ishida, Takashi ; Suzuki, Susumu ; Ito, Asahi ; Narita, Tomoko ; Kinoshita, Shiori ; Ri, Masaki ; Kusumoto, Shigeru ; Komatsu, Hirokazu ; Inagaki, Hiroshi ; Ueda, Ryuzo ; Iida, Shinsuke</creator><creatorcontrib>Masaki, Ayako ; Ishida, Takashi ; Suzuki, Susumu ; Ito, Asahi ; Narita, Tomoko ; Kinoshita, Shiori ; Ri, Masaki ; Kusumoto, Shigeru ; Komatsu, Hirokazu ; Inagaki, Hiroshi ; Ueda, Ryuzo ; Iida, Shinsuke</creatorcontrib><description>Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease.
The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><identifier>DOI: 10.1111/cas.13654</identifier><identifier>PMID: 29845702</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>adult T‐cell leukemia/lymphoma ; Antigens ; Apoptosis ; Asymptomatic ; Cell death ; CTL ; Cytokines ; Cytotoxicity ; Gene Products, tax - immunology ; HTLV-I Infections - immunology ; HTLV‐1 ; Human T-lymphotropic virus 1 - immunology ; Humans ; Immunoglobulins ; Laboratories ; Leukemia ; Leukemia-Lymphoma, Adult T-Cell - immunology ; Lymphocytes ; Lymphocytes T ; Lymphoma ; Original ; Peptides ; Peripheral blood mononuclear cells ; Pharmaceuticals ; Programmed Cell Death 1 Receptor - immunology ; programmed cell death protein 1 ; Proteins ; R&D ; Research & development ; Research funding ; Risk factors ; T-Lymphocytes, Cytotoxic - immunology ; Tax ; Tumor necrosis factor-TNF</subject><ispartof>Cancer science, 2018-08, Vol.109 (8), p.2383-2390</ispartof><rights>2018 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</citedby><cites>FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</cites><orcidid>0000-0002-1060-0777 ; 0000-0002-9617-486X ; 0000-0002-4951-960X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113433/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113433/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1416,11561,27923,27924,45573,45574,46051,46475,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29845702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Masaki, Ayako</creatorcontrib><creatorcontrib>Ishida, Takashi</creatorcontrib><creatorcontrib>Suzuki, Susumu</creatorcontrib><creatorcontrib>Ito, Asahi</creatorcontrib><creatorcontrib>Narita, Tomoko</creatorcontrib><creatorcontrib>Kinoshita, Shiori</creatorcontrib><creatorcontrib>Ri, Masaki</creatorcontrib><creatorcontrib>Kusumoto, Shigeru</creatorcontrib><creatorcontrib>Komatsu, Hirokazu</creatorcontrib><creatorcontrib>Inagaki, Hiroshi</creatorcontrib><creatorcontrib>Ueda, Ryuzo</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><title>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</title><title>Cancer science</title><addtitle>Cancer Sci</addtitle><description>Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease.
The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients.</description><subject>adult T‐cell leukemia/lymphoma</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Asymptomatic</subject><subject>Cell death</subject><subject>CTL</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Gene Products, tax - immunology</subject><subject>HTLV-I Infections - immunology</subject><subject>HTLV‐1</subject><subject>Human T-lymphotropic virus 1 - immunology</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Leukemia-Lymphoma, Adult T-Cell - immunology</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Original</subject><subject>Peptides</subject><subject>Peripheral blood mononuclear cells</subject><subject>Pharmaceuticals</subject><subject>Programmed Cell Death 1 Receptor - immunology</subject><subject>programmed cell death protein 1</subject><subject>Proteins</subject><subject>R&D</subject><subject>Research & development</subject><subject>Research funding</subject><subject>Risk factors</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tax</subject><subject>Tumor necrosis factor-TNF</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kctu1DAUhiMEoqWw4AVQJDbtIp3j-3iDVI2AQRqJBQNby3FOGJckDnEydHaIJ-AZeRI8nbZcJLBknSP70ycf_1n2lMA5SWvmbDwnTAp-LzsmjOtCAcj7170qNDB6lD2K8RKASa75w-yI6jkXCuhx9m05tbbL1z--fnfYNHmza_tNGIfQezdrcPqErbf51g9TzMddjznJT5fr1YfEk7N8ba9SE3t0vvbulwWvNnaKow9d7rv8lk_bdzW6Eat0XPmtrybbxMfZgzoVfHJTT7L3r16uF8ti9fb1m8XFqnBcC14gnxNbga11hYBWa6pZSUARV8pSYa0sEboEyTRIUTEirXJi7mpXEaIsMHaSvTh4-6lssXLYjYNtTD_41g47E6w3f950fmM-hq2RJH0k2wtObwRD-DxhHE3r435e22GYoqHAFRVEcEjo87_QyzANXRrPUC7nQgAB_l-KaqBUEi0TdXag3BBiHLC-ezIBs8_fpPzNdf6Jffb7jHfkbeAJmB2AL77B3b9NZnHx7qD8CY70vzk</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Masaki, Ayako</creator><creator>Ishida, Takashi</creator><creator>Suzuki, Susumu</creator><creator>Ito, Asahi</creator><creator>Narita, Tomoko</creator><creator>Kinoshita, Shiori</creator><creator>Ri, Masaki</creator><creator>Kusumoto, Shigeru</creator><creator>Komatsu, Hirokazu</creator><creator>Inagaki, Hiroshi</creator><creator>Ueda, Ryuzo</creator><creator>Iida, Shinsuke</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1060-0777</orcidid><orcidid>https://orcid.org/0000-0002-9617-486X</orcidid><orcidid>https://orcid.org/0000-0002-4951-960X</orcidid></search><sort><creationdate>201808</creationdate><title>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</title><author>Masaki, Ayako ; Ishida, Takashi ; Suzuki, Susumu ; Ito, Asahi ; Narita, Tomoko ; Kinoshita, Shiori ; Ri, Masaki ; Kusumoto, Shigeru ; Komatsu, Hirokazu ; Inagaki, Hiroshi ; Ueda, Ryuzo ; Iida, Shinsuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4954-e481ad0af9de0ea99293b1071cb6b7ef7a159b0639065d316a7c58cfcd117a033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>adult T‐cell leukemia/lymphoma</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Asymptomatic</topic><topic>Cell death</topic><topic>CTL</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Gene Products, tax - immunology</topic><topic>HTLV-I Infections - immunology</topic><topic>HTLV‐1</topic><topic>Human T-lymphotropic virus 1 - immunology</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Leukemia-Lymphoma, Adult T-Cell - immunology</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Original</topic><topic>Peptides</topic><topic>Peripheral blood mononuclear cells</topic><topic>Pharmaceuticals</topic><topic>Programmed Cell Death 1 Receptor - immunology</topic><topic>programmed cell death protein 1</topic><topic>Proteins</topic><topic>R&D</topic><topic>Research & development</topic><topic>Research funding</topic><topic>Risk factors</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tax</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Masaki, Ayako</creatorcontrib><creatorcontrib>Ishida, Takashi</creatorcontrib><creatorcontrib>Suzuki, Susumu</creatorcontrib><creatorcontrib>Ito, Asahi</creatorcontrib><creatorcontrib>Narita, Tomoko</creatorcontrib><creatorcontrib>Kinoshita, Shiori</creatorcontrib><creatorcontrib>Ri, Masaki</creatorcontrib><creatorcontrib>Kusumoto, Shigeru</creatorcontrib><creatorcontrib>Komatsu, Hirokazu</creatorcontrib><creatorcontrib>Inagaki, Hiroshi</creatorcontrib><creatorcontrib>Ueda, Ryuzo</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Masaki, Ayako</au><au>Ishida, Takashi</au><au>Suzuki, Susumu</au><au>Ito, Asahi</au><au>Narita, Tomoko</au><au>Kinoshita, Shiori</au><au>Ri, Masaki</au><au>Kusumoto, Shigeru</au><au>Komatsu, Hirokazu</au><au>Inagaki, Hiroshi</au><au>Ueda, Ryuzo</au><au>Iida, Shinsuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals</atitle><jtitle>Cancer science</jtitle><addtitle>Cancer Sci</addtitle><date>2018-08</date><risdate>2018</risdate><volume>109</volume><issue>8</issue><spage>2383</spage><epage>2390</epage><pages>2383-2390</pages><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>Adult T‐cell leukemia/lymphoma (ATL) is caused by Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1), and a higher HTLV‐1 provirus load in PBMC is a risk factor for ATL development. Here, we document a significant inverse correlation between the function of HTLV‐1 Tax‐specific CTL (Tax‐CTL), as assessed by ex vivo cytokine production in response to cognate peptide, and the HTLV‐1 provirus load in PBMC in both HTLV‐1 asymptomatic carriers (AC) (Spearman rank correlation coefficient [Rs] = −0.494, P = .037, n = 18) and ATL patients (Rs = −0.774, P = .001, n = 15). There was also a significant correlation between the HTLV‐1 provirus load and the percentage of PD‐1‐positive Tax‐CTL in both HTLV‐1 AC (Rs = 0.574, P = .013) and ATL patients (Rs = 0.676, P = .006). Furthermore, the percentage of PD‐1‐positive Tax‐CTL was inversely correlated with their function in HTLV‐1 AC (Rs = −0.542, P = .020), and ATL patients (Rs = −0.639, P = .010). These findings indicate that the function of Tax‐CTL decreased as their programmed cell death protein 1 (PD‐1) levels increased, parallel to the increased HTLV‐1 provirus load in PBMC. We propose that functional Tax‐CTL are crucial for determining the HTLV‐1 provirus load in PBMC, not only in HTLV‐1 AC, but also in ATL, and that PD‐1 expression levels are reliable markers of Tax‐CTL function. Thus, modulating the immunological equilibrium between Tax‐CTL and HTLV‐1‐infected cells to achieve dominance of functional effectors could represent an ideal strategy for controlling HTLV‐1‐associated disease.
The functional integrity of Tax‐CTL is crucial for determining HTLV‐1 provirus load in PBMC not only in HTLV‐1 AC, but also in ATL patients.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>29845702</pmid><doi>10.1111/cas.13654</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1060-0777</orcidid><orcidid>https://orcid.org/0000-0002-9617-486X</orcidid><orcidid>https://orcid.org/0000-0002-4951-960X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1347-9032 |
ispartof | Cancer science, 2018-08, Vol.109 (8), p.2383-2390 |
issn | 1347-9032 1349-7006 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6113433 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Wiley-Blackwell Open Access Titles; Wiley Online Library All Journals; PubMed Central |
subjects | adult T‐cell leukemia/lymphoma Antigens Apoptosis Asymptomatic Cell death CTL Cytokines Cytotoxicity Gene Products, tax - immunology HTLV-I Infections - immunology HTLV‐1 Human T-lymphotropic virus 1 - immunology Humans Immunoglobulins Laboratories Leukemia Leukemia-Lymphoma, Adult T-Cell - immunology Lymphocytes Lymphocytes T Lymphoma Original Peptides Peripheral blood mononuclear cells Pharmaceuticals Programmed Cell Death 1 Receptor - immunology programmed cell death protein 1 Proteins R&D Research & development Research funding Risk factors T-Lymphocytes, Cytotoxic - immunology Tax Tumor necrosis factor-TNF |
title | Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A12%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20T%E2%80%90cell%20lymphotropic/leukemia%20virus%20type%201%20(HTLV%E2%80%901)%20Tax%E2%80%90specific%20T%E2%80%90cell%20exhaustion%20in%20HTLV%E2%80%901%E2%80%90infected%20individuals&rft.jtitle=Cancer%20science&rft.au=Masaki,%20Ayako&rft.date=2018-08&rft.volume=109&rft.issue=8&rft.spage=2383&rft.epage=2390&rft.pages=2383-2390&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/10.1111/cas.13654&rft_dat=%3Cproquest_pubme%3E2468550104%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2290226196&rft_id=info:pmid/29845702&rfr_iscdi=true |